Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGCT 2021 | Developing novel TCR-based T cell products for cancer therapy

Chiara Bonini, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Institute, Milan, Italy, provides an overview of ongoing research presented at the 2021 European Society of Gene & Cell Therapy (ESGCT) Congress focusing on optimizing protocols and generating new T-cell receptor (TCR)-based T cell products. She describes a T cell hunting project that identified TCRs with high affinity to specific molecular targets such as PD-1, the development of efficient protocols to express leading TCR candidates into T cells using CRISPR TCR gene editing and the exploitation of the multiplex capacity of CRISR technology to tackle tumor immunosuppressive pathways by disrupting T cell inhibitory receptor genes. This interview took place at the ESGCT Virtual Congress 2021.